Vivus’ Qnexa Works “Surprisingly” Well In Diabetes
This article was originally published in The Pink Sheet Daily
Executive Summary
Obesity drug could double its market opportunity, analysts say.
You may also be interested in...
R&D IN BRIEF
Barr's adenovirus vaccines constitute its first biologics BLA: Barr's adenovirus types 4 and 7 live oral vaccines carry an FDA user fee date of July 31, 2009, making it the company's first in-house biologics to reach FDA review. Barr, through its Duramed subsidiary, entered into a multi-year agreement in 2001 to develop the vaccines for the U.S. Department of Defense. The vaccine product is administered as an oral enteric-coated tablet with an inner tablet core containing live adenovirus - type 4 or type 7 - surrounded by an outer tablet coat and a final enteric coat. The type 4 and type 7 vaccine tablets are taken together to prevent wild type 4 adenovirus-associated acute respiratory disease and to induce neutralizing antibody to type 7 adenovirus. The BLA is supported by a Phase III placebo-controlled study in more than 4,000 male and female Navy and Army recruits
R&D IN BRIEF
Barr's adenovirus vaccines constitute its first biologics BLA: Barr's adenovirus types 4 and 7 live oral vaccines carry an FDA user fee date of July 31, 2009, making it the company's first in-house biologics to reach FDA review. Barr, through its Duramed subsidiary, entered into a multi-year agreement in 2001 to develop the vaccines for the U.S. Department of Defense. The vaccine product is administered as an oral enteric-coated tablet with an inner tablet core containing live adenovirus - type 4 or type 7 - surrounded by an outer tablet coat and a final enteric coat. The type 4 and type 7 vaccine tablets are taken together to prevent wild type 4 adenovirus-associated acute respiratory disease and to induce neutralizing antibody to type 7 adenovirus. The BLA is supported by a Phase III placebo-controlled study in more than 4,000 male and female Navy and Army recruits
Vivus Poised To Enter Phase III With Obesity Candidate Qnexa
Firm touts safety advantage of experimental phentermine/topiramate combination therapy.